Metgli 2mg/500mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet and exercise alone. Metgli 2mg/500mg Tablet PR is typically prescribed when monotherapy with either agent is insufficient, offering improved efficacy with a reduced risk of hypoglycemia compared to sulfonylurea monotherapy. It is essential to initiate treatment with appropriate lifestyle modifications including diet and exercise, and to monitor blood glucose levels regularly. Contraindications include renal impairment, metabolic acidosis, and hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia. Dose adjustment may be necessary in patients with renal or hepatic impairment. Regular monitoring of renal function and glycemic parameters is recommended during therapy.

Dosage & How to Use